In Vitro Assessment of Cardiac Risk in Drug Discovery

Clear decision-making data for your project team is vital to ensure you avoid costly issues related to QTc and QRS cardiac liabilities in the clinic. Hear from industry experts, Derek Leishman (VP Translational and Quantitative Toxicology, Eli Lilly and Company) and Steve Jenkinson (Metrion).

Recommended Publications

Latest Publications

Webinar recording: Recent Progress Towards a Potential Treatment for KCNC-1 Related Disorders

This webinar presents the patient perspective, electrophysiological research, and technologies used as we work towards a potential treatment for KCNC1-related disorders.

Metrion Biosciences High Throughput Screening Services

Here we share a short video introducing Metrion’s expanded high throughput screening capabilities. To learn more, or to request a quote, please email info@metrionbiosciences.com

View All

Recording and Q&A from webinar 'Recent Progress Towards a Potential Treatment for KCNC1-Related Disorders'

Webinar recording: Recent Progress Towards a Potential Treatment for KCNC-1 Related Disorders

View All